Morning may matter: new trial tests timing of melanoma treatment
NCT ID NCT07155317
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 29 times
Summary
This study tests whether giving immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than other times of day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV or unresectable melanoma will be randomly assigned to morning, afternoon, or evening treatment. The goal is to see if timing can improve how long the cancer stays under control and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Emory Saint Joseph's Hospital
NOT_YET_RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.